IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

217

Participants

Timeline

Start Date

August 30, 2013

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Metastatic Breast Cancer
Interventions
PROCEDURE

Molecular imaging

On the day of FES-injection\&scan or the day after FES-injection, 89Zr-trastuzumab (\~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.

PROCEDURE

Molecular imaging

All patients receive 18F-FES (\~200MBq) injection followed by a FES-PET.

Trial Locations (3)

Unknown

VU University Medical Center, Amsterdam

University Medical Center St. Radboud, Nijmegen

9700RB

University Medical Center, Groningen

All Listed Sponsors
collaborator

Amsterdam UMC, location VUmc

OTHER

collaborator

University Medical Center Nijmegen

OTHER

lead

University Medical Center Groningen

OTHER

NCT01957332 - IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter